Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C25H26O6 |
Molecular Weight | 422.4703 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CO[C@@H](CC1=CC=C(OCCCOC2=CC=C(OC3=CC=CC=C3)C=C2)C=C1)C(O)=O
InChI
InChIKey=OKJHGOPITGTTIM-DEOSSOPVSA-N
InChI=1S/C25H26O6/c1-28-24(25(26)27)18-19-8-10-20(11-9-19)29-16-5-17-30-21-12-14-23(15-13-21)31-22-6-3-2-4-7-22/h2-4,6-15,24H,5,16-18H2,1H3,(H,26,27)/t24-/m0/s1
Molecular Formula | C25H26O6 |
Molecular Weight | 422.4703 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Naveglitazar is an oral dual peroxisome proliferator-activated receptor (PPAR) agonist, which was under development with Ligand Pharmaceuticals for the treatment of type 2 diabetes mellitus. Naveglitazar is a nonthiozolidinedione peroxisome proliferator-activated receptor (PPAR) α-γ dual, γ-dominant agonist that has shown glucose-lowering potential in animal models and in the clinic. Naveglitazar had been in phase II clinical trials for the once-daily oral treatment of type 2 diabetes, however, the development was discontinued.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700659 |
1.71 µM [IC50] | ||
Target ID: CHEMBL235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700659 |
0.024 µM [IC50] |
PubMed
Title | Date | PubMed |
---|---|---|
The disposition and metabolism of naveglitazar, a peroxisome proliferator-activated receptor alpha-gamma dual, gamma-dominant agonist in mice, rats, and monkeys. | 2007 Jan |
|
Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. | 2008 |
|
Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-gamma Agonist. | 2008 |
|
Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. | 2008 Feb |
|
Allometric prediction of the human pharmacokinetic parameters for naveglitazar. | 2008 Jul-Sep |
|
Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. | 2009 Oct |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700659
The carcinogenic potential of naveglitazar, a gamma-dominant peroxisome proliferator-activated receptor (PPAR) alpha/gamma dual agonist, was evaluated in a two-year study in F344 rats (0, 0.3, 1.0, or 3.0 mg/kg, males; 0, 0.1, 0.3, or 1.0 mg/kg, females). Rats were randomly assigned to treatment groups based on
weight. Rats (60/sex/group) were assigned to groups receiving
0, 0.3, 1.0, or 3.0 mg naveglitazar/kg body weight/day (males)
or 0, 0.1, 0.3, or 1.0 mg naveglitazar/kg body weight/day
(females) by oral gavage.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19700659
In vitro, naveglitazar binds selectively to PPAR g with high affinity (IC50 =0.024 uM, Ki = 0.022uM) and to PPAR a with lower affinity (IC50 =1.71 uM, Ki = 1.66 uM)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:18:40 GMT 2023
by
admin
on
Fri Dec 15 16:18:40 GMT 2023
|
Record UNII |
Y995M7GM0G
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98233
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
9888484
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
C517861
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
CHEMBL181954
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
C75191
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
Y995M7GM0G
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
8472
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
PP-41
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
DTXSID70870358
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
DB12662
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
476436-68-7
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY | |||
|
300000034359
Created by
admin on Fri Dec 15 16:18:40 GMT 2023 , Edited by admin on Fri Dec 15 16:18:40 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> AGONIST |
|
||
|
TARGET -> AGONIST |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|